Credit Suisse Leaves AbbVie Management Meeting Feeling Optimistic

Loading...
Loading...

Two analysts from Credit Suisse met with members of the management team from AbbVie Inc ABBV including the CEO and CFO. They inquired about the recent Stemcentrx acquisition and AbbVie’s oncology franchise. They left the meeting feeling “more comfortable” with the long-term prospects for the company.

Related Link: AbbVie Gets Europe's Approval For Imbruvica For Chronic Lymphocytic Leukemia Treatment

One area of interest was the outlook for AbbVie’s flagship product, Humira. Humira has been in the news lately due to Amgen, Inc. AMGN’s biosimilar product, but Credit Suisse said it expects AbbVie to file suit against Amgen, likely in the third quarter.

Management believes that once investors are able to appreciate fully the protection AbbVie has around Humira, they’ll be confident that biosimilars won’t enter the U.S. market until around 2022.

Credit Suisse holds an Outperform rating on AbbVie with a $67 price target, representing 14 percent upside from where shares closed Monday.

date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechLong IdeasHealth CarePrice TargetReiterationAnalyst RatingsTrading IdeasGeneralCredit SuisseStemcentrx
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...